As medical professionals specializing in regenerative medicine, we approach SLE with a commitment to evidence‑based, mechanism‑focused explanation. Our framework recognizes that successful supportive outcomes often require addressing multiple contributing factors simultaneously: immune dysregulation, chronic inflammation, and end‑organ effects (kidney, skin, joints).
We emphasize transparent communication regarding the current scientific understanding of MSC paracrine and immunomodulatory dynamics, the importance of supportive therapies (physical therapy, nutrition), and the need for realistic expectations. Each plan is individualized based on comprehensive evaluation, autoantibody profile, and specific organ involvement.
Our practice maintains a focus on safety, minimally invasive techniques, and thorough follow‑up to monitor progress and adjust supportive interventions as needed.
— Nexus Regenerative Medicine Clinical Team
Medically reviewed by Dr. Guillermo Quezada, MD – May 2026 (regenerative medicine specialist) | Content reviewed as of March 2026
MSC therapy for systemic lupus erythematosus is not approved by the U.S. FDA, Mexican COFEPRIS (for this indication), or any other regulatory agency. It is considered an adjunctive, experimental procedure.
Costs are discussed only after a consultation.